 |
|
|
|
 |
|
|
| Article 1 to 10 out of 13 concerning Eisai Co., Ltd
|
-
Eisai Opens Regional Office in Bahrain
(19 Oct 2009)
Eisai Co., Ltd. announced the opening of a regional office in Bahrain. The new office has been established as a branch of its Asian headquarters Eisai Asia Regional Services Pte. Ltd.Eisai started doing business with the Middle East in the 1960’s. ...
-
Eisai Receives Approval for a New Oral Jelly Formulation of Aricept for the Treatment of Alzheimer’s Disease in Japan
(24 Jul 2009)
Eisai Co., Ltd. announced that the Company had received approval for a new oral jelly formulation of Aricept® (donepezil hydrochloride) for the treatment of Alzheimer’s disease from the Japanese Ministry of Health, Labour and Welfare. The new oral ...
-
SymBio Pharmaceuticals and Eisai Sign License Agreement for bendamustine hydrochloride (SyB L-0501)
(19 Aug 2008)
SymBio Pharmaceuticals Limited. and Eisai Co., Ltd. announced that the companies have concluded the license agreement for the co-development and commercialization of bendamustine hydrochloride in Japan, with exclusive rights retained by SymBio.Based ...
-
Eisai invests in BioArctic's Alzheimer research
(07 Apr 2008)
Japanese firm inputs world-leading know-how in next-generation treatment
Eisai Co. Ltd has signed an exclusive licence agreement with Uppsala-based biopharmaceutical company BioArctic Neuroscience for their monoclonal antibody BAN2401, developed as a next-generation treatment for Alzheimer's Disease. The amount invested ...
-
M's Science and Eisai Sign Option Agreement for Sigma Agonist SA4503
(14 Mar 2008)
M's Science Corporation and Eisai Co., Ltd. announced that the companies entered into an option agreement for SA4503, a novel sigma agonist which is being developed by M's Science in Europe for the treatment of depression and post-stroke ...
-
Eisai, the First Japanese Pharmaceutical Firm to Open Regional Clinical Research Centre in Singapore
(06 Dec 2007)
Eisai Co., Ltd, announced the opening of its Regional Clinical Research Centre in Singapore - Eisai Clinical Research Singapore Pte Ltd. It is the first Japanese Pharmaceutical Company to do so here, recognising Singapore's enormous growth in the ...
-
Eisai Announces Completion of Acquisition of Morphotek
(18 Apr 2007)
Eisai Co., Ltd. and Eisai Corporation of North America announced the completion of Eisai's acquisition of Morphotek® Inc. after having cleared the approval process by the government authorities including the U.S. Federal Trade Commission. The ...
-
Eisai Licenses Selective Estrogen Receptor Modulators (SERMs) to Radius
(05 Jul 2006)
Radius announced that it has acquired exclusive worldwide rights, excluding Japan, to a new class of selective estrogen receptor modulators (SERMs) discovered by Eisai Co., Ltd. Radius is currently advancing its first development candidate from this ...
-
Dainippon and Eisai Signed Licensing Agreement for A Potential New Treatment for Diabetic Neuropathy
(04 Oct 2005)
Dainippon Pharmaceutical Co., Ltd and Eisai Co., Ltd. signed an exclusive licensing agreement for AS-3201, a potential new treatment for diabetic neuropathy that was discovered and is being developed by Dainippon Pharmaceutical. Under the agreement, ...
-
Eisai Announces Strategic Alliance With BioArctic Neuroscience To Develop Immunotherapy For Alzheimer's Disease
(30 Aug 2005)
Eisai Co., Ltd. and BioArctic Neuroscience Inc. announced that on August 24, they signed a strategic alliance agreement to develop an immunotherapy for Alzheimer's disease. Based on this agreement, Eisai will obtain first right of refusal for drug ...
|
|
|
|
|
Top